Stockscreener 앱 받기
60.26
1.78%
-1.09
시간 외 거래:
59.80
-0.46
-0.76%
Biomarin Pharmaceutical Inc 주식(BMRN)의 최신 뉴스
BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board - simplywall.st
Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - GlobeNewswire Inc.
BioMarin Pharmaceutical stock falls 1.38 percent on Nasdaq - AD HOC NEWS
BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts - sg.finance.yahoo.com
BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 — Here’s Why - Stocktwits
BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish - AD HOC NEWS
BioMarin Pharmaceutical Inc. (BM8.F) stock price, news, quote and history - Yahoo Finance UK
BioMarin Pharmaceutical stock holds near its 52-week low - AD HOC NEWS
BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. (BMRN): Stock Analysis Reveals 43% Potential Upside - DirectorsTalk Interviews
The Best Healthcare Stocks to Buy - Morningstar
BioMarin Pharmaceutical stock holds near a $12.38 billion value - AD HOC NEWS
BMRN Q2 2026 Earnings: EPS Beats Estimates by 4.05% While Shares Slip 1.75%Earnings Outlook Update - careplusvn.com
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? - finance.yahoo.com
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone - Yahoo Finance
BioMarin options flow shows large bullish call spread targeting $100 by April 2027 - Investing.com
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo Finance
BioMarin Stops Voxzogo Development for Noonan Syndrome - The Globe and Mail
BMO cuts BioMarin stock price target to $97 on Voxzogo focus shift - Investing.com Nigeria
BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) - kalkinemedia.com
BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts - Fierce Pharma
BioMarin Announces Discontinuation of VOXZOGO Development for Pediatric Noonan Syndrome - kalkinemedia.com
BioMarin to discontinue development of Voxzogo for Noonan syndrome in children - Investing.com
BMRN Looks 21.8% Undervalued on GF Value™ Amid Pipeline Shift - GuruFocus
BioMarin shelves Voxzogo in Noonan syndrome (BMRN:NASDAQ) - Seeking Alpha
Form 8K Biomarin Pharmaceutical Inc For: 15 September By Investing.com - Investing.com Canada
BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan
BioMarin Pharmaceutical Inc. Announces Appointment of Robert Plenge to Its Board of Directors and Science and Technology Committee, Effective September 10, 2026 - marketscreener.com
BioMarin Pharmaceutical appoints Robert Plenge to board of directors By Investing.com - Investing.com Nigeria
BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board - citybiz
Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com - Investing.com Nigeria
BioMarin appoints Bristol Myers Squibb executive to board - Investing.com
BioMarin appoints Robert Plenge to its Board and Science & Technology Committee - TradingView
BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors - prnewswire.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Forms Tight Breakout Setup With Strong Technicals - ChartMill
BioMarin Shares Jump 5% After Global Patent Settlement With Ascendis - Yahoo Finance
BioMarin at Citi summit: voxzogo drives growth as pipeline widens - Investing.com
BMRN: Blockbuster growth, pipeline innovation, and AI-driven efficiencies drive future outlook - TradingView
BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook - TradingView
BioMarin at Cantor conference: growth plan widens beyond Voxzogo By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Biomarin stock rating at neutral By Investing.com - Investing.com South Africa
Ascendis Pharma Says Growth Drug Shows Benefits in Infants - Benzinga
H.C. Wainwright reiterates Biomarin stock rating at neutral - Investing.com
BioMarin at Wells Fargo conference: growth, pipeline and integration - Investing.com India
BioMarin at Wells Fargo conference: growth, pipeline and integration By Investing.com - Investing.com Canada
BMRN: Strong growth, pipeline expansion, and global market execution drive future momentum - TradingView
(BMRN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BioMarin Pharmaceutical Inc. Announces Positive Results Of Phase 3 VOXZOGO Study In Hypochondroplasia - marketscreener.com
BioMarin Announces Positive Results of Phase 3 VOXZOGO® Study in Hypochondroplasia Published in NEJM Evidence - Investing News Network
Ten healthcare stocks with A-rated valuations and strong revenue growth - TradingView
BioMarin pads case for Voxzogo expansion as achondroplasia competition field shifts - Fierce Pharma
A drug helped children with a rare growth disorder grow 2.33 cm more per year - Stock Titan
Don't Ignore The Insider Selling In BioMarin Pharmaceutical - simplywall.st
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
3 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN) - simplywall.st
Weekly Recap: TransCon CNP license and Alesta Therapeutics acquisition - TradingView
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: 37% Upside Potential Amid Robust Revenue Growth - DirectorsTalk Interviews
3.06%
2.55%
자본화:
|
볼륨(24시간):